César López-CamachoPeter AbbinkRafael A. LaroccaWanwisa DejnirattisaiMichael BoydAlex Badamchi-ZadehZoë R. WallaceJennifer DoigRicardo Sanchez VelazquezRoberto Dias Lins NetoDanilo F. CoelhoYoung Chan KimClaire L. DonaldAnia OwsiankaGiuditta De LorenzoAlain KohlSarah C. GilbertLucy DorrellJuthathip MongkolsapayaArvind H. PatelGavin R. ScreatonDan H. BarouchAdrian V.S. HillArturo Reyes-SandovalUniversity of OxfordFundacao Oswaldo CruzImperial College LondonFaculty of Medicine, Siriraj Hospital, Mahidol UniversityNuffield Department of Clinical MedicineHarvard Medical SchoolUniversity of Glasgow2019-08-232019-08-232018-12-01Nature Communications. Vol.9, No.1 (2018)204117232-s2.0-85048986838https://repository.li.mahidol.ac.th/handle/123456789/44982© 2018 The Author(s). Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ΔTM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryPhysics and AstronomyArticleSCOPUS10.1038/s41467-018-04859-5